The American Congress of OB/GYN (ACOG) initially supported Ther-Rx’s application to the FDA for Makena. When the astronomical price, a hike from $10 to $1500 a shot, was announced ACOG released this statement:
ACOG is extremely concerned that women’s health may be shortchanged by this high price tag, and we’re asking Ther-Rx to reconsider it’s pricing and to ensure women have full access to this important drug.
Then on April 1, 2011 after Ther-Rx announced the price reduction from $1,500 to $695 a dose, ACOG issued a statement calling the reduction “inadequate” and applauded the “US Food and Drug Administration’s (FDA) statement that it will not prevent compounding pharmacies from continuing to produce valid prescriptions for 17P, a medication that has been safely used for years to help prevent preterm labor in certain high-risk pregnant women.”
So that’s all good. ACOG takes a stand on the price and supports the FDA’s decision to not interfere with compounding.
So imagine my surprise when I received this month’s Obstetrics & Gynecology, ACOG’s monthly journal. It was wrapped with a nice paper announcing the only FDA approved therapy for preterm birth. And inside, a lovely full page glossy add for Makena.
Hey ACOG dudes!
Issuing public statements about the pricing atrocity and how it will burden the already overpriced American system of health care is great and all, but it’s a pretty poor double standard when you are accepting advertising dollars from the very company you accuse of extorting the public.
If your advertising department is so out of touch with, you know, your message can we expect cigarette ads sometime soon?
Just saying. Because it’s stuff like this that makes me wonder if denouncing Makena was more about saving face than important things, like making sure every woman who needs 17 hydroxyprogesterone actually has access to the drug at a reasonable price.